On the basis of pre-clinic evidence indicating that inhibition of HER2 increases radiation sensitivity of breast cancers [13–15, 35], a combination treatment with radiation and HER2 inhibitors (trastuzumab or lapatinib) is currently under investigation in clinical trials [36]. Here, ERBB2 is linked to breast carcinoma.